Final diagnoses. All patients (n = 254) included 142 males (56%) and 112 females (44%) with a mean age of 30 years (range, 1-75 years). Diagnoses included ∼25% nonneoplastic (e.g. reactive lymphadenitis or staging marrows) and ∼75% neoplastic entities. Chronic myeloid leukemia (CML) diagnosis was confirmed by BCR-ABL testing performed at BWH or, starting in December 2016, local testing in Rwanda. Remaining entities include plasma cell neoplasm (PCN) (4%), BL (2%), and nonheme malignancy (2%). ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CHL, classical Hodgkin lymphoma; NHL, non-Hodgkin lymphoma.